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Abstract
Mitochondria play a key role in common neurodegenerative diseases and contain their own genome: mtDNA.
Common inherited polymorphic variants of mtDNA have been associated with several neurodegenerative diseases,
and somatic deletions of mtDNA have been found in affected brain regions. However, there are conflicting reports
describing the role of rare inherited variants and somatic point mutations in neurodegenerative disorders, and
recent evidence also implicates mtDNA levels. To address these issues we studied 1363 post mortem human brains
with a histopathological diagnosis of Parkinson’s disease (PD), Alzheimer’s disease (AD), Frontotemporal dementia –
Amyotrophic Lateral Sclerosis (FTD-ALS), Creutzfeldt Jacob disease (CJD), and healthy controls. We obtained
high-depth whole mitochondrial genome sequences using off target reads from whole exome sequencing to
determine the association of mtDNA variation with the development and progression of disease, and to better
understand the development of mtDNA mutations and copy number in the aging brain. With this approach, we
found a surprisingly high frequency of heteroplasmic mtDNA variants in 32.3% of subjects. However, we found no
evidence of an association between rare inherited variants of mtDNA or mtDNA heteroplasmy and disease. In
contrast, we observed a reduction in the amount of mtDNA copy in both AD and CJD. Based on these findings,
single nucleotide variants of mtDNA are unlikely to play a major role in the pathogenesis of these
neurodegenerative diseases, but mtDNA levels merit further investigation.
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Introduction
Mitochondria are critical intracellular organelles in-
volved in calcium signaling, lipid biosynthesis, apoptosis
[31], and the generation of adenosine triphosphate
(ATP) via the mitochondrial respiratory chain [28]. Over
the last decade it has become clear that mitochondria
play a key role in the pathogenesis of common neurode-
generative disorders. Mitochondria contain their own
16.5 kb circular mitochondria genome (mtDNA), which
codes for key components of the mitochondrial prote-
ome. MtDNA is present in 10s-1000s of copies in each
cell and undergoes lifelong replication in post-mitotic
cells including neurons [10]. With rudimentary mecha-
nisms for repair, mtDNA is vulnerable to mutations,
which accumulate within cells and also within the germ
line.
There is emerging evidence that genetic variation of
mtDNA contributes to the pathogenesis of neurodegener-
ative disorders [14]. Common population genetic variants
divide the human population into a geographically-
defined ‘haplogroups’ [30], which have been associated
with several neurodegenerative disorders including
Alzheimer’s disease (AD) and Parkinson’s disease (PD),
conferring a small increase in disease risk [13, 22].
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Furthermore, high-density genotyping arrays provide
preliminary evidence that rare (minor allele frequency,
MAF <5%) mtDNA polymorphisms are also associated
with neurodegenerative disease, supporting previous work
on AD [12].
In addition to maternally inherited polymorphisms,
acquired somatic mutations of mtDNA have also been
associated with neurodegenerative disorders. Unlike the
maternally inherited germ line variants (which are ‘homo-
plasmic’), the somatic mutations are usually present along-
side the original wild-type molecules (heteroplasmy), and
the proportion of mutated alleles determines whether a
biochemical defect is manifest at the cellular level. MtDNA
deletions accumulate in the ageing brain, reaching higher
levels in regions vulnerable to neurodegeneration [3, 26],
but evidence describing the accumulation of somatic point
mutations or small insertion-deletion mutations (indels) is
less compelling, with conflicting reports in the literature [6,
20]. Finally, several recent studies have described abnormal
amounts of mtDNA both in cerebrospinal fluid or the
brains of patients with neurodegenerative diseases [23, 24],
but only in a limited number of individuals.
To provide definitive evidence in all three areas, we
studied the entire mtDNA sequence and quantity in1363
post mortem brains with Alzheimer’s disease (AD),
Amyotrophic-frontotemporal dementia (ALS-FTD),
Creutzfeldt-Jakob Disease (CJD), Parkinson’s disease (PD)
and Dementia with Lewy Bodies (DLB), and compared
them to healthy age-matched control brains. We found no
evidence that rare inherited polymorphisms or mtDNA
heteroplasmy contributes to the pathogenesis of neurode-
generative diseases, although differences in mtDNA con-
tent provide a clue to disease mechanism in AD and CJD.
Materials and methods
Study samples
Full mitochondrial genome sequence data was extracted
from Exome Sequencing data of 1363 case or control
brain tissue samples from the Medical Research Council
Brain Tissue Resource [15]. Cases fulfilling both ante-
mortem and post-mortem diagnostic criteria for major
neurodegenerative disease were included (Table 1,
Additional file 1: Methods, Additional file 1: Table S1).
DNA was extracted from the cerebellum in 87.3% of
cases (n = 1190), cerebral cortex in 6.5% of cases (n = 89)
with other brain regions in 6.16% (n = 84).
Mitochondrial sequences extraction and variant calling
Exome sequencing was performed using Nextera 62 Mb
Rapid Capture Expended Exome kits on the Illumina
HiSeq 2000 with 100 bp paired-end reads. Sequence data
were aligned to the human reference sequence (UCSC
hg19) (http://genome.ucsc.edu) using Burrows-Wheeler
Aligner (BWA) v0.7.6 [17], formatted using Samtools
v0.1.19 [18], and duplicates removed using Picard v1.707
(http://picard.sourceforge.net).
MToolBox [4] recovered mtDNA from off-target
sequences, remapped onto the revised Cambridge Refer-
ence Sequence [2], and discarded those mapping to
regions of (GRCh37/hg19), and considered Nuclear
mitochondrial Sequences [29].
Known insertions or deletions (ins/dels) were defined,
and all variants scored in HmtDB [27] and MITOMAP
[28]. Remaining reads reconstructed the mitochondrial
genome. Nucleotide mismatches and ins/del with quality
scores (QS ≥25) and read depth (rd ≥5) were included.
Determining heteroplasmy and homoplasmy
We determined the proportion of variant alleles at each
site of the mitochondrial genome. We then calculated
the heteroplasmic fraction (HF, %) by dividing the num-
ber of variant reads by the total number of reads (for
SNVs and deletions) or of the total number of 5′ flank-
ing reads (for insertions). If the HF was <10% or >90%,
we conservatively considered the variant site to be
homoplasmic. If the HF was between 10 and 90%, the
Table 1 Clinical and demographic data of all cases within the study
Number of cases (n) Age onset (years) Age of death (years) Female Male
Age SD Age SD n % n %
AD 282 67.0 11.2 78.1 11.6 152 53.9 130 46.1
CJD 181 54.2 19.6 55.1 19.2 96 53.0 85 47.0
Control 351 78.1 12.0 196 55.8 155 44.2
DLB-PD 89 63.9 10.3 75.1 8.5 31 34.8 58 65.2
FTD-ALS 236 58.9 11.2 64.4 11.5 98 41.5 137 58.1
Young Controls 110 41.4 9.7 30 27.3 80 72.7
Other disorders (See Additional file 1: Tables S1-S8) 114 60.3 21.5 72.7 16.7 46 40.3 68 59.7
Mean 60.6 17.2 69.0 17.4 43.9 56.1
Total 1363 598 765
Key: AD Alzheimer’s disease, CJD Creutzfeldt Jacob Disease, DLB-PD Dementia with Lewy Bodies or Parkinson’s disease, FTD-ALS Frontotemporal Dementia or
Amyotrophic Lateral Sclerosis. Information about Other disorders can be seen in Additional file 1: Table S2
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site was considered to be heteroplasmic, and the HF was
studied further.
Defining mtDNA haplogroups
Haplogroup assignment was performed using the mt-
classifier tool [32], and a maximum likelihood (ML)
phylogenetic tree was created using the PHYLIP soft-
ware (v3.696) from sequence alignments built by Clustal
Omega (v1.2.0) (http://www.clustal.org/omega). Defined
haplogroups were compared to the haplogroups geno-
typed in 2360 individuals from the 1958 Birth Cohort
(WTCCC58C) as previously determined by Hudson et
al. [11].
Defining rare variants
Minor allele frequencies for each base of the mitochon-
drial genome were calculated from 30,506 full-length
mitochondrial sequences in NCBI-GenBank using cus-
tom Python scripts. Rare homoplasmic variations were
defined as those alleles present in less than 5% of indi-
viduals within their haplogroup using MITOMASTER
[21], and novel variants those not present in the NCBI-
GenBank dataset, 1000 genomes [9], MITOMAP [28] or
HmDB [27].
Functional prediction
Pathogenicity scores for all possible non-haplogroup de-
fining SNVs were calculated using MutPred [19] and
Polyphen-2 [1].
MtDNA copy number estimation
The relative amount of mtDNA in each brain (referred
to as mtDNA copy number) was calculated as the ratio
between the mean mtDNA read depth and the mean
exome read depth as previously described [5].
Statistical analysis
Mean variant counts or fractions both within and
between groups were performed using Mann-Whitney,
Fisher’s exact, or Spearman’s rank test tests as appropri-
ate and as defined at the uncorrected threshold. A Pois-
son loglinear model was used to test the association
between the number of variants and age among individ-
uals within each main group. All statistical analyses were
performed using R (v3.0.2) (http://CRAN.R-project.org/
doc/FAQ/R-FAQ.html), and plots made using Python.
Results
Coverage and quality of assembled mitochondrial
genomes
Complete assembly of the mitochondrial genome was
obtained in all cases, with a mean read depth across the
genome of 289 (SD = 169.8) (range 66–1328) and a mean
base quality score of 36.8 (sd = 0.25) (range 36.0–37.5)
(Additional file 1: Figures S1 and S2). There was no dif-
ference in mean read depth or mean base quality score
for any group vs controls (Additional file 1: Figure S3).
Haplogroup associations
Haplogroups and phylogenetic relationships were deter-
mined for all 1363 samples (Fig. 1). There was no differ-
ence in major overall haplogroup frequency when
compared to 2360 UK population controls (Additional
file 1: Table S2), confirming the accuracy of haplogroup
calling and that the cohort as representative of the UK
population. We saw no association between any disease
cohort and specific haplogroups in our study (Additional
file 1: Table S3).
Homoplasmic variants
One thousand, nine hundred twenty-three homoplasmic
variants were detected within the cohort, with a mean of
22.9 (sd = 10.8) variants per sample. Four hundred sixty-
seven variants were defined as ‘common’ (minor popula-
tion Allele Frequency, MpAF >0.05 within their
haplogroup), and included known haplogroup defining
variants. One thousand, four hundred fifty-six homo-
plasmic variants were defined as rare (MpAF <0.05
within their haplogroup). Twenty-five of the rare
variants were novel, not seen in the NCBI database (n =
30,506), MITOMAP (n = 30,589) or the 1000 genomes
database. Four of the novel variants were in non-coding
regions, two were in rRNA genes, and 19 were synonym-
ous (Additional file 1: Table S4).
Association with disease – common homoplasmic
variants
Here we considered all homoplasmic variants, and a
subgroup analysis of all non-synonymous homoplasmic
variants. We saw no evidence of a disease association
with any single variant, the burden of homoplasmic vari-
ants in any gene, nor the burden of homoplasmic
variants in groups of genes forming a respiratory chain
complex (Additional file 1: Figures S4–S8, Additional file
1: Table S5). However, when stratifying by age, there was
a trend towards young onset AD cases (age of death
<60) having a greater number of total variants in MT-TR
compared to controls (6/13 vs 9/139) (p = 0.002)
(Additional file 1: Figure S5).
Association with disease - rare homoplasmic variants
No single rare homoplasmic variant was present at
greater frequency in any disease compared to controls
(Additional file 1: Figure S8). There was a trend towards
a greater number of rare homoplasmic point mutations
in two genes in AD compared to controls; MT-RNR1
(AD; 30/282 (10.6%), Controls; 16/344 (4.7%)) (p =
0.005)) and again MT-TR (AD; 6/282 (2.1%), Controls; 0/
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344) (p = 0.008), although both failed to reach signifi-
cance at the corrected threshold of p = 0.0014.
(Additional file 1: Figure S8, Additional file 1: Table S5).
When stratified by age, this suggested that the trend to-
wards an excess burden of rare homoplasmic variants in
MT-RNR1 was likely driven by variants in young onset
AD cases vs controls (AD: 9/53 (16.9%), Controls (2/65),
p = 0.012 (3%) (Additional file 1: Figure S9). We also saw
that young onset PD-DLB cases (death aged <70) had a
significantly greater number of rare homoplastic muta-
tions in MT-CO2 (PD-DLB: 5/23 (21.7%), Controls: 5/
213 (2.3%), p = 0.0010 (Additional file 1: Figure S9). The
majority of the variants in MT-CO2 in both cohorts were
in non-coding D-loop, but when combined this did not
reach the corrected threshold for significance. There was
no association between any rare non-synonymous
variant, nor the burden of rare non-synonymous variants
in any gene or respiratory chain complex in any disease
group vs controls.
Heteroplasmic variants
Three hundred eleven heteroplasmic variants (>10%
MAF) were detected (mean HF = 7%, sd = 1.0), in 440
cases, with 10 of these variants entirely novel. 55.7% of
all heteroplasmic variants occurred within the D-loop,
33.3% in coding regions, 4.8% in rRNA genes and 6.2%
in tRNA genes (Fig. 2).
There was no association between any disease group
and controls for any single heteroplasmic variant, the
total number of heteroplasmic variants, or the mean
variant pathogenicity score. There was also no
association between the number of non-synonymous
Fig. 1 Phylogenetic tree of the 1363 mtDNA sequenced derived from the MRC Brain Tissue Resource. Major haplogroups are shown
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heterozygous variants in any gene or complex and any
disease group compared to controls (Additional file 1:
Tables S6–S8, Additional file 1: Figure S12).
Heteroplasmy and age
We subsequently used a Poison loglinear model to de-
termine the relationship between heteroplasmy and age
within each group. There was no age correlation with
the total number of heteroplasmic variants, mean level
of heteroplasmy (HF), nor the mean variant pathogen-
icity score in any disease group (Fig. 3).
mtDNA number
mtDNA copy number was significant lower in AD and CJD
compared to controls (p= 2.85 × 10−7 (AD), p= 3.34 × 10−7
(CJD)), and we observed a strongly positive correlation
between age and mtDNA copy number in CJD (p= 2.7 × 10
−11). No association with age was seen in other groups
(Fig. 4). The frequency of cerebellar samples in the AD
cohort was no different to controls (p= 0.64) or the FTD-
ALS cohort (p= 0.87). However, the CJD cohort did show a
greater proportion of cases from the cerebellum compared
to all other cohorts (100%, p < 0.001 vs all other groups).
Discussion
Here we report a comprehensive study of mtDNA
sequence variation and abundance in brain tissue from
1363 neuropathologically characterized post mortem
samples from MRC Brain Tissue Resource. After correc-
tion for multiple significance testing, we saw no differ-
ence in the frequency of mtDNA haplogroups, no
difference in the frequency of common or rare
Fig. 2 Circos plot summarizing all of the genetic data from 1363 sequences derived form the MRC Brain Tissue Resource. From outside the circle to
inside: (1) mtDNA position, (2) mtDNA genes, (3) mtDNA Complex, (4) frequency of variants in 40,440 mitochondrial sequences in NCBI-GenBank, (5)
mean read depth of 1363 samples per base, (6) Total variants in all 1363 samples [circles], (7) Total Rare variants in 1363 samples [triangles], (8) Total
novel variants in 1363 samples [squares]. Colour code for circles (6) – (8): Red - AD, green - ALS-FTD, blue - CJD, yellow - DLB-PD, grey - others; from
inner to outer, HF increasing. Key – AD –Alzheimer’s disease, CJD – Creutzfeldt Jacob Disease, DLB-PD – Dementia with Lewy Bodies or Parkinson’s
disease, FTD-ALS – Frontotemporal Dementia or Amyotrophic Lateral Sclerosis
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homoplasmic variants, and no difference in the presence
or degree of mtDNA heteroplasmy between different
disease groups and control subjects. Overall, we
conclude that neither rare homoplasmic variants nor
heteroplasmic variants play a substantial role in the
pathogenesis of these disorders. However, further work
is required to clarify whether mtDNA copy number is
important for the pathogenesis of AD and CJD.
Our most interesting finding was the frequent
occurrence of mtDNA heteroplasmy in human brain
tissue (HF >10% found in 32.3% of cases and con-
trols), but contrary to previous reports, this did not
change with age, nor was it associated with disease.
This suggests that, although ongoing replication
errors in mtDNA occur with age [16, 25], moderate
level heteroplasmic variants (>10%) are likely to have
either occurred de novo in early development, or have
been inherited within the germ-line, perhaps clonally
expanding to these levels in early life. Resolving this
issue will be difficult in human subjects, but will re-
quire the analysis of serial samples from the same tis-
sue in the same subject. We cannot exclude the
possibility that low level heteroplasmy (MAF <10%) is
associated with these different disorders, or that
different regions of the brain contain a significant
burden of mtDNA variants, as recently described [8].
However, if low level heteroplasmic variants are im-
portant (perhaps because the low mean level masks
high levels in individual neurons or glia), it is surpris-
ing that the higher levels of heteroplasmy we
detected were not associated with disease, and that
patient brains did not contain more pathogenic muta-
tions than control subjects.
Finally we observed a significant reduction in
mtDNA copy number in both Alzheimer’s disease and
CJD brains. Our data support previous work in AD
[7], but to our knowledge is the first study of mtDNA
copy number in CJD brain tissue. It is possible that
the CJD finding reflects the higher proportion of
cerebellar samples studied when compared to con-
trols. In addition, the mtDNA copy number in the
variant CJD (vCJD) cases (n = 40, mean mtDNA copy
number = 4.14, sd = 2.96) was lower than all other
CJD types (mean = 10.03, sd = 7.67; p = 2.8 × 10−6).
Therefore, it is therefore also possible that the trend
observed for CJD actually reflects unusually low levels
of mtDNA in the brains from patients with vCJD,
who died at a younger age than other forms of CJD.
Fig. 3 The distribution and nature of major heteroplasmic mtDNA variation within 1363 cases from the MRC Brain Bank Tissue Resource. a Top left – The
mean number of heteroplasmic variants per sample in each cohort. b Top right - The distribution of heteroplasmic fraction (ratio of mutant to wild-type
allele) for heteroplasmic variants for each disease cohort. c Bottom left – The mean number of heteroplasmic point mutations by age for each disease
cohort. d Bottom right – The mean heteroplasmic fraction by age for each disease cohort. Key – AD –Alzheimer’s disease, CJD – Creutzfeldt Jacob Disease,
DLB-PD – Dementia with Lewy Bodies or Parkinson’s disease, FTD-ALS – Frontotemporal Dementia or Amyotrophic Lateral Sclerosis
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Conclusion
When taken together, these findings support the role of
mtDNA content in the pathogenesis of neurodegenere-
tive diseases, but with caveats. First, the abnormalities
may be restricted to specific brain regions. Previous
studies in PD showed a reduction in mtDNA copy num-
ber within the substantia nigra, but not frontal cortex,
raising the possibility that the altered mtDNA levels are
a consequence of the underlying pathology, and not the
cause. This could be an indirect effect reflecting a
change in the proportion of different cell types within a
tissue homogenate that is linked to the neurodegenera-
tion. Nonetheless, the observed association between
mtDNA copy number and age in CJD brains supports a
causal role which requires further investigation. Al-
though this could reflect compensatory mitochondrial
biogenesis in older subjects, an alternative explanation is
that younger-onset cases have more aggressive path-
ology, with associated neuronal loss.
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Additional file 1: Supplementary Material. (DOCX 6597 kb)
Acknowledgements
This work was funded by the UK Medical Research Council (13044). MJK is a
Wellcome Trust Clinical Research Training Fellow. PFC is a Wellcome Trust
Senior Fellow in Clinical Science (101876/Z/13/Z), and a UK NIHR Senior
Investigator, who receives support from the Medical Research Council
Mitochondrial Biology Unit (MC_UP_1501/2), the Wellcome Trust Centre for
Mitochondrial Research (096919Z/11/Z), the Medical Research Council (UK)
Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the
National Institute for Health Research (NIHR) Biomedical Research Centre
based at Cambridge University Hospitals NHS Foundation Trust and the
University of Cambridge. The views expressed are those of the author(s) and
not necessarily those of the NHS, the NIHR or the Department of Health. We
thank Thahira Rahman and Mikyung Jang for assistance in initial the
database management. We are grateful to Dr Mark Head, Ms Helen Yull and
Ms Suzanne Lowrie for tissue sampling, DNA extraction and management of
the CJD samples used in this study.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WW performed the primary bioinformatic analysis with MJK and HG,
supervised by MSK. IW performed statistical analysis. MJK co-ordinated the
study with JC, S Ryan, S Rollinson, M K-A, C-A McK, & CT. KT, MRT, JA, CS,
SAS, CMM, and OA supervised the neuropathological and collection of the
clinical data. SPB supervised the C9ORF72 repeat analysis. PFC and JI
supervised the entire study study and obtained funding. MJK and PFC wrote
the first draft manuscript which was modified following contributions from
the other authors. All authors read and approved the final manuscript.
Author details
1Institute of Genetic Medicine, Central Parkway, Newcastle University,
Newcastle Upon Tyne NE1 3BZ, UK. 2Institute of Brain, Behaviour and Mental
Health, University of Manchester, 2.014 AV Hill Building, Oxford Road,
Manchester M13 9PT, UK. 3Department of Clinical Neurosciences, John
Radcliffe Hospital, Level 3, West Wing, Headley Way, Oxford OX3 9DU, UK.
4National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences,
University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK.
5Department of Basic and Clinical Neuroscience, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, De Crespigny Park,
London SE5 8AF, UK. 6Department of Neuropathology, John Radcliffe
Hospital, West Wing, Level 1, Oxford OX3 9DU, UK. 7Department of Clinical
Neurosciences, University of Cambridge, University Neurology Unit, Level 5
‘A’ Block, Box 165 Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.
8MRC Mitochondrial Biology Unit, Cambridge Biomedical Campus,
Cambridge CB2 0QQ, UK.
Received: 13 December 2016 Accepted: 13 December 2016
References
1. Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for
predicting damaging missense mutations. Nat Methods 7(4):248–9
2. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell
N (1999) Reanalysis and revision of the Cambridge reference sequence for
human mitochondrial DNA. Nat Genet 23(2):147
3. Bender A, Krishnan KJ, Morris CM et al (2006) High levels of mitochondrial
DNA deletions in substantia nigra neurons in aging and Parkinson disease.
Nat Genet 38(5):515–7
4. Calabrese C, Simone D, Diroma MA et al (2014) MToolBox: a highly
automated pipeline for heteroplasmy annotation and prioritization analysis
of human mitochondrial variants in high-throughput sequencing.
Bioinformatics 30(21):3115–7
5. Castle JC, Biery M, Bouzek H et al (2010) DNA copy number, including
telomeres and mitochondria, assayed using next-generation sequencing.
BMC Genomics 11:244
Fig. 4 The relative mtDNA copy number in each disease cohort.
a Top – Relative copy number of each cohort calculated as the ratio
between the mean mtDNA read depth and the mean exome read
depth as previously described [5]. ** (P < 0.01). b Bottom - The
association between relative mtDNA copy number and age for all
CJD cases (n = 182) with the Spearman Rank ρ and p-value shown.
Key – AD –Alzheimer’s disease, CJD – Creutzfeldt Jacob Disease, DLB-PD –
Dementia with Lewy Bodies or Parkinson’s disease, FTD-ALS – Frontotem-
poral Dementia or Amyotrophic Lateral Sclerosis
Wei et al. Acta Neuropathologica Communications  (2017) 5:13 Page 7 of 8
6. Chinnery PF, Taylor GA, Howell N, Brown DT, Parsons TJ, Turnbull DM (2001)
Point mutations of the mtDNA control region in normal and
neurodegenerative human brains. Am J Hum Genet 68(2):529–32
7. Coskun PE, Beal MF, Wallace DC (2004) Alzheimer’s brains harbor somatic
mtDNA control-region mutations that suppress mitochondrial transcription
and replication. Proc Natl Acad Sci U S A 101(29):10726–31
8. Coxhead J, Kurzawa-Akanbi M, Hussain R, Pyle A, Chinnery P, Hudson G
(2016) Somatic mtDNA variation is an important component of Parkinson’s
disease. Neurobiol Aging 38:217, e1-6
9. Diroma MA, Calabrese C, Simone D et al (2014) Extraction and annotation
of human mitochondrial genomes from 1000 Genomes Whole Exome
Sequencing data. BMC Genomics 15(Suppl 3):S2
10. Elson JL, Samuels DC, Turnbull DM, Chinnery PF (2001) Random intracellular
drift explains the clonal expansion of mitochondrial DNA mutations with
age. Am J Hum Genet 68(3):802–6
11. Gleeson JG, Minnerath S, Kuzniecky RI et al (2000) Somatic and germline
mosaic mutations in the doublecortin gene are associated with variable
phenotypes. Am J Hum Genet 67(3):574–81
12. Hudson G, Gomez-Duran A, Wilson IJ, Chinnery PF (2014) Recent
mitochondrial DNA mutations increase the risk of developing common late-
onset human diseases. PLoS Genet 10(5):e1004369
13. Hudson G, Nalls M, Evans JR et al (2013) Two-stage association study and
meta-analysis of mitochondrial DNA variants in Parkinson disease.
Neurology 80(22):2042–8
14. Keogh MJ, Chinnery PF (2015) Mitochondrial DNA mutations in
neurodegeneration. Biochim Biophys Acta 1847(11):1401–11
15. Keogh MJ, Wei W, Wilson I, et al. Genetic compendium of 1511 human
brains available through the UK Medical Research Council Brain Banks
Network Resource. Genome Res. 2016. In press.
16. Larsson NG (2010) Somatic mitochondrial DNA mutations in mammalian
aging. Annu Rev Biochem 79:683–706
17. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25(14):1754–60
18. Li H, Handsaker B, Wysoker A et al (2009) The sequence alignment/Map
format and SAMtools. Bioinformatics 25(16):2078–9
19. Li B, Krishnan VG, Mort ME et al (2009) Automated inference of molecular
mechanisms of disease from amino acid substitutions. Bioinformatics
25(21):2744–50
20. Lin MT, Cantuti-Castelvetri I, Zheng K et al (2012) Somatic mitochondrial
DNA mutations in early Parkinson and incidental Lewy body disease. Ann
Neurol 71(6):850–4
21. Lodato MA, Woodworth MB, Lee S et al (2015) Somatic mutation in single
human neurons tracks developmental and transcriptional history. Science
350(6256):94–8
22. Maruszak A, Canter JA, Styczynska M, Zekanowski C, Barcikowska M (2009)
Mitochondrial haplogroup H and Alzheimer’s disease–is there a connection?
Neurobiol Aging 30(11):1749–55
23. Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G (2016)
Reduced mitochondrial DNA copy number is a biomarker of Parkinson’s
disease. Neurobiol Aging 38:216, e7-10
24. Pyle A, Brennan R, Kurzawa-Akanbi M et al (2015) Reduced cerebrospinal
fluid mitochondrial DNA is a biomarker for early-stage Parkinson’s disease.
Ann Neurol 78(6):1000–4
25. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and
cancer stem cells. Nature 414(6859):105–11
26. Ross JM, Stewart JB, Hagstrom E et al (2013) Germline mitochondrial DNA
mutations aggravate ageing and can impair brain development. Nature
501(7467):412–5
27. Rubino F, Piredda R, Calabrese FM et al (2012) HmtDB, a genomic resource
for mitochondrion-based human variability studies. Nucleic Acids Res
40(Database issue):D1150–9
28. Ruiz-Pesini E, Lott MT, Procaccio V et al (2007) An enhanced MITOMAP with
a global mtDNA mutational phylogeny. Nucleic Acids Res 35(Database
issue):D823–8
29. Simone D, Calabrese FM, Lang M, Gasparre G, Attimonelli M (2011) The
reference human nuclear mitochondrial sequences compilation validated
and implemented on the UCSC genome browser. BMC Genomics 12:517
30. Torroni A, Richards M, Macaulay V et al (2000) mtDNA haplogroups and
frequency patterns in Europe. Am J Hum Genet 66(3):1173–7
31. van der Giezen M, Tovar J (2005) Degenerate mitochondria. EMBO Rep
6(6):525–30
32. van Oven M, Kayser M (2009) Updated comprehensive phylogenetic tree of
global human mitochondrial DNA variation. Hum Mutat 30(2):E386–94
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wei et al. Acta Neuropathologica Communications  (2017) 5:13 Page 8 of 8
